Therefore, although further investigation is important, the potential utility of DPP‐4 inhibitors for the treatment of a broad spectrum of metabolic disorders related to obesity via the activation of BAT function in humans is still of interest. Here, DPP4 is linked to obesity due to melanocortin 4 receptor deficiency.